



ASX release

2 February 2010

Central BP a superior determinant of Left Ventricular Hypertrophy

--New study highlights importance of central pressure in patient care and clinical trials

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness noninvasively, today announced a new National Institutes of Health (NIH)-funded study¹, published in the Journal of Hypertension, has found that central (aortic) blood pressure, measured noninvasively, is a more important indicator of the development of left ventricular hypertrophy (LVH) than is brachial blood pressure. LVH relates to muscle thickening in the heart's pumping chamber. Its incidence increases with age and is more common in people who have high blood pressure.

The study, which included data from 2,585 participants in the Strong Heart study, concluded that its results lent support to the "growing body of data indicating that central pressure is a more important determinant of cardiovascular target organ damage, morbidity, and mortality than brachial blood pressure."

"This new publication reinforces the vital importance of measuring central blood pressure, in clinical trials and in patient care," said Duncan Ross, AtCor Medical President and CEO.

"Left ventricular hypertrophy is a major risk factor for heart failure, heart attack and stroke. This is more evidence that shows it is vitally important to measure central blood pressure to identify patients at risk, effectively manage hypertension therapy and assess the impact of positive lifestyle changes."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 799 8221

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au

¹ Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. Roman et al. Journal of Hypertension 2010, Vol 28 No 00